MedTrace Logo

Identification of Ascitic Fluid Bacterial Pathogens in Spontaneous Bacterial Peritonitis

NCT02463721 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2018-01-03

No results posted yet for this study

Summary

Several studies have pointed out changes in the epidemiology of the causative bacteria in SBP and bacterascites and in their susceptibility to antibiotics. In particular, the development of beta-lactamase enzymes, which confer resistance to clavulanate, or extended spectrum beta-lactamases in Escherichia coli. The potential emergence of enterococci, methicillin-resistant S. aureus, or fluoroquinolone-resistant bacteria, following norfloxacin prophylaxis, is also a cause of concern since they may be associated with a higher risk of therapeutic failure.

The microbial etiology of SBP remains relatively constant; however, the antibiotic resistance rate especially for third-generation cephalosporins (including cefotaxime and ceftazidime), ciprofloxacin, and ofloxacin increased dramatically

Conditions

  • Primary Bacterial Peritonitis

Interventions

OTHER

ascitic fluid culture and microbiological testing

ascitic fluid culture and microbiological testing for 100 patients with liver cirrhosis and ascites with suspicion of SBP

Sponsors & Collaborators

  • Tanta University

    lead OTHER

Principal Investigators

  • Sherief Abd-elsalam, lecturer · hepatology dept-Tanta

  • Sally Elnawasany, lecturer · hepatology dept-Tanta

  • WALAA eLKHALAWANY, lecturer · hepatology dept-Tanta

Study Design

Allocation
NA
Purpose
DIAGNOSTIC
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-01-31
Primary Completion
2019-12-31
Completion
2019-12-31

Countries

  • Egypt

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02463721 on ClinicalTrials.gov